New drug duo aims to wipe out rectal tumors before surgery
NCT ID NCT04503694
Summary
This trial is testing whether adding two drugs, regorafenib and nivolumab, to standard short-course radiation can better shrink rectal tumors before surgery. The goal is to see if this combination leads to a complete disappearance of the tumor, potentially allowing some patients to avoid surgery. It involves 72 adults with stage 2 or 3 rectal cancer who are eligible for curative treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER STAGE II are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Groeninge
Kortrijk, 8500, Belgium
-
CHR Namur
Namur, 5000, Belgium
-
CHU Ambroise Paré
Mons, 7000, Belgium
-
Chirec Delta
Brussels, 1160, Belgium
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Grand Hopital de Charleroi
Gilly, 6060, Belgium
-
Institut Jules Bordet
Anderlecht, 1070, Belgium
-
UZ Gent
Ghent, 9000, Belgium
-
UZAntwerpen
Edegem, 2650, Belgium
Conditions
Explore the condition pages connected to this study.